Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esomeprazole + sodium bicarbonate is an immediate-release oral combination therapy developed to treat acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and Zollinger–Ellison syndrome. Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells, thereby reducing stomach acidity. Sodium bicarbonate acts as an antacid, neutralizing existing stomach acid and protecting esomeprazole from degradation in the acidic environment of the stomach, which allows for faster absorption and onset of action compared to enteric-coated formulations. This combination is particularly useful for patients requiring rapid symptom relief or those who cannot tolerate delayed-release formulations[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esomeprazole + sodium bicarbonate.